Results 121 to 130 of about 626,377 (227)
PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report
Frontiers in Cardiovascular MedicineBackgroundApproximately 3.8 million patients in China suffer from familial hypercholesterolemia (FH). Statins and PCSK9 inhibitors are recommended by guidelines as therapeutic agents.
Yuan Li +4 more
doaj +1 more source
Clinical Cardiology, Volume 49, Issue 10, October 2026.Genomic medicine in cardiovascular care is progressing from established diagnostic applications toward integrated risk prediction, multiomics, and emerging therapeutic strategies. ABSTRACT Background Genomic cardiology is an emerging field integrating genetic, molecular, imaging, and digital health data to improve cardiovascular disease (CVD ...
Neda Mohsen‐Pour +5 more
wiley +1 more source
Angewandte Chemie, Volume 138, Issue 40, 28 September 2026.Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee +5 more
wiley +2 more sources
Vascular Health and Risk Management, 2016 Sanjiv Gupta Department of Interventional Cardiology, Santokba Durlabhji Memorial Hospital Cum Medical Research Institute, Jaipur, India Abstract: The aim of this manuscript is to review available data to evaluate the present status of proprotein ...
Gupta S
doaj
Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 5, October 2026.ABSTRACT Background Urolithin A (UA) and urolithin B (UB) are gut microbiota‐derived metabolites of ellagitannins reported to influence mitochondrial function, inflammation and muscle metabolism. Their comparative transcriptomic effects in human skeletal muscle cells remain undefined.
Yves Henrotin +8 more
wiley +1 more source
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
MedComm, Volume 7, Issue 10, October 2026.Hypertriglyceridemia (HTG) arises from the interplay between genetic susceptibility and secondary or precipitating factors, leading to dysregulated triglyceride‐rich lipoprotein (TRL) metabolism. Increased TRL production and impaired clearance promote distinct risk phenotypes: accumulation of apolipoprotein B(apoB)‐containing TRL remnants contributes ...
Shanshan Qi +9 more
wiley +1 more source
TP53 Mutation Heterogeneity Refines Prognostic Stratification in IDH‐Wildtype Glioma
MedComm, Volume 7, Issue 10, October 2026.This study reveals that TP53 mutations in IDH‐wildtype gliomas are prognostically heterogeneous. A variant allele frequency (VAF) ≥10% identifies a high‑risk subgroup, and mutations located in the β‑strand region of the DNA‑binding domain confer the poorest outcomes.
Kuilin Liao +16 more
wiley +1 more source
The pharmacology of pcsk9 inhibitors
, 2017 Hypercholesterolemia, a condition marked by high levels of cholesterol in the blood affects over 30 million adults in the USA and is responsible for 2.6 million deaths and 29.7 million disability life adjusted years worldwide.
Alshuqayh, Salem
core
Pcsk9 inhibitors and cardiovascular disease: Impact on cardiovascular outcomes
, 2020 Cardiovascular Disease (CVD) remains the leading cause of morbidity and mortality in the western world. Hypolipidemic drugs have long been used for the primary and secondary prevention of heart disease.
Diamantis, E. +5 more
core +1 more source
α‐Synuclein Promotes Atherosclerosis by Impairing Macrophage Autophagic Flux
Aging Cell, Volume 25, Issue 10, October 2026.Extracellular α‐synuclein activates the FLOT1‐PI3K‐mTOR axis to block autophagosome‐lysosomal fusion and lipophagy, thereby promoting macrophage foaming and atherosclerosis. Knockdown of FLOT1 or inhibition of PI3K‐mTOR rescues these effects. The graphical abstract image was created with Figdraw.
Mengting Qin +8 more
wiley +1 more source